Unknown

Dataset Information

0

Pharmacogenetic factors affecting β-blocker metabolism and response.


ABSTRACT:

Introduction

β-blockers are among the most widely prescribed of all drugs, used for treatment of a large number of cardiovascular diseases. Herein we evaluate literature pertaining to pharmacogenetics of β-blocker therapy, provide insight into the robustness of the genetic associations, and determine the appropriateness for translating these genetic associations into clinical practice.

Areas covered

A literature search was conducted using PubMed to collate evidence on associations between CYP2D6, ADRB1, ADRB2, and GRK5 genetic variation and drug-response outcomes in the presence of β-blocker exposure. Pharmacokinetic, pharmacodynamic, and clinical outcomes studies were included if genotype data and β-blocker exposure were documented.

Expert opinion

Substantial data suggest that specific ADRB1 and GRK5 genotypes are associated with improved β-blocker efficacy and have potential for use to guide therapy decisions in the clinical setting. While the data do not justify ordering a CYP2D6 pharmacogenetic test, if CYP2D6 genotype is available in the electronic health record, there may be clinical utility for understanding dosing of β-blockers.

SUBMITTER: Thomas CD 

PROVIDER: S-EPMC7606773 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6537658 | biostudies-literature
| S-EPMC3785800 | biostudies-literature
| S-EPMC1264912 | biostudies-other
| S-EPMC2851851 | biostudies-literature
2016-12-22 | GSE86793 | GEO
| S-EPMC4760893 | biostudies-literature
2014-02-14 | E-GEOD-54130 | biostudies-arrayexpress
| S-EPMC1187803 | biostudies-other
| 2071360 | ecrin-mdr-crc
| S-EPMC2675574 | biostudies-literature